Vantage Financial Partners Ltd. Inc. lowered its holdings in shares of Biogen Inc (NASDAQ:BIIB) by 13.2% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,000 shares of the biotechnology company’s stock after selling 304 shares during the quarter. Vantage Financial Partners Ltd. Inc.’s holdings in Biogen were worth $638,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. boosted its stake in Biogen by 77.0% during the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 400 shares of the biotechnology company’s stock worth $127,000 after buying an additional 174 shares in the last quarter. Horan Capital Advisors LLC. bought a new position in shares of Biogen during the third quarter valued at $128,000. Massey Quick Simon & CO. LLC lifted its holdings in shares of Biogen by 84.8% during the third quarter. Massey Quick Simon & CO. LLC now owns 425 shares of the biotechnology company’s stock valued at $133,000 after acquiring an additional 195 shares during the period. Cable Hill Partners LLC lifted its holdings in shares of Biogen by 224.7% during the third quarter. Cable Hill Partners LLC now owns 487 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 337 shares during the period. Finally, Denali Advisors LLC bought a new position in shares of Biogen during the fourth quarter valued at $159,000. Hedge funds and other institutional investors own 89.20% of the company’s stock.
Shares of Biogen Inc (BIIB) opened at $291.87 on Tuesday. The company has a quick ratio of 2.07, a current ratio of 2.34 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $61,748.80, a PE ratio of 24.49, a P/E/G ratio of 1.52 and a beta of 0.75. Biogen Inc has a 12-month low of $244.28 and a 12-month high of $370.57.
Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Thursday, January 25th. The biotechnology company reported $5.26 EPS for the quarter, missing the Zacks’ consensus estimate of $5.44 by ($0.18). The firm had revenue of $3.31 billion during the quarter, compared to analyst estimates of $3.08 billion. Biogen had a return on equity of 38.32% and a net margin of 20.69%. Biogen’s revenue for the quarter was up 15.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.04 earnings per share. analysts anticipate that Biogen Inc will post 24.88 EPS for the current year.
A number of research analysts have issued reports on the company. Argus cut Biogen from a “buy” rating to a “hold” rating in a report on Friday. Canaccord Genuity set a $350.00 price objective on Biogen and gave the company a “hold” rating in a report on Thursday, February 15th. William Blair reissued a “buy” rating on shares of Biogen in a report on Thursday, February 15th. BidaskClub cut Biogen from a “buy” rating to a “hold” rating in a report on Thursday, February 15th. Finally, Credit Suisse Group raised Biogen to a “buy” rating and set a $384.00 price objective for the company in a report on Wednesday, February 7th. Ten analysts have rated the stock with a hold rating and twenty-three have issued a buy rating to the company’s stock. Biogen currently has a consensus rating of “Buy” and a consensus price target of $368.99.
In other news, CEO Michel Vounatsos acquired 780 shares of the stock in a transaction that occurred on Friday, December 29th. The stock was purchased at an average cost of $320.55 per share, for a total transaction of $250,029.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert W. Pangia sold 5,832 shares of Biogen stock in a transaction dated Tuesday, January 9th. The stock was sold at an average price of $329.65, for a total value of $1,922,518.80. Following the completion of the sale, the director now owns 23,539 shares of the company’s stock, valued at $7,759,631.35. The disclosure for this sale can be found here. Over the last quarter, insiders purchased 31,560 shares of company stock valued at $10,020,858. Corporate insiders own 0.25% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Vantage Financial Partners Ltd. Inc. Sells 304 Shares of Biogen Inc (BIIB)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. & international copyright and trademark laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/20/vantage-financial-partners-ltd-inc-sells-304-shares-of-biogen-inc-biib.html.
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc (NASDAQ:BIIB).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.